Drug Profile

ITC 6146RO

Alternative Names: ITC-6146RO

Latest Information Update: 26 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ab Studio; IntoCell
Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

26 Feb 2026 ITC 6146RO is still in preclinical for Cancer in South Korea (IntoCell pipeline, February 2026)
20 Feb 2026 IntoCell plans a phase Ia/b trial for Cancer (Metastatic disease, Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable) in February 2026 (NCT07423117)
28 Nov 2025 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com